MDWD - MediWound Ltd.
| Previous Close | 9.71 |
| Open | 9.76 |
| Bid | 9.52 x 1100 |
| Ask | 9.66 x 800 |
| Day's Range | 9.40 - 9.98 |
| 52 Week Range | 8.05 - 15.72 |
| Volume | |
| Avg. Volume | 19,577 |
| Market Cap | 92.479M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.63 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.00 |
Simply Wall St.Analyst Forecasts Just Became More Bearish On MediWound Ltd. (NASDAQ:MDWD)
The analysts covering MediWound Ltd. ( NASDAQ:MDWD ) delivered a dose of negativity to shareholders today, by making a...
ZacksMediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of -41.94% and 28.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireMediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
On track to initiate EscharEx® Phase III study in fourth quarter 2023NexoBrid® U.S. launch expected in early third quarter 2023Cash of over $57 million; Operating cash runway through profitability Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2023 and provided
- GlobeNewswire
MediWound to Report First Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern TimeYAVNE, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 on Tuesday, May 30, 2023. Following the release, MediWound's management will host a conference call and live webcast at 8:30am Eastern Time to discu
- GlobeNewswire
MediWound Announces an Additional $10 Million Award from BARDA
Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extensionYAVNE, Israel, May 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within
- GlobeNewswire
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
Data to be highlighted in oral and poster presentations YAVNE, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic solutions for tissue repair, today announced the Company will present updated clinical data from the three EscharEx® Phase 2 trials at the 2023 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society taking place in National Harbor, Maryland on April 26-30, 2023. In
- Simply Wall St.
Pinning Down MediWound Ltd.'s (NASDAQ:MDWD) P/S Is Difficult Right Now
You may think that with a price-to-sales (or "P/S") ratio of 4.4x MediWound Ltd. ( NASDAQ:MDWD ) is a stock to...
- Simply Wall St.
We Think MediWound (NASDAQ:MDWD) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
MediWound Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
MediWound ( NASDAQ:MDWD ) Full Year 2022 Results Key Financial Results Revenue: US$26.5m (up 12% from FY 2021). Net...
ZacksMediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
2022 total revenues of $26.5 million FDA approval of NexoBrid® in December 2022; U.S. commercial availability expected in the second quarter of 2023 EscharEx® Phase III protocol design is under review by the FDA; study to be initiated in the second half of 2023 Cash position of $66 million, including cash received for the NexoBrid approval milestone and recent equity financing Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd.
- GlobeNewswire
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound’s Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the
ZacksMediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development Appoints Alicia Torrenova, as Vice President of European Operations Both bring extensive leadership experience and expertise in wound care and regenerative medicine YAVNE, Israel, March 06, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announc
- GlobeNewswire
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern TimeYAVNE, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2022 on Thursday, March 16, 2023. Following the release, MediWound's management wil
- GlobeNewswire
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced management will present at two upcoming investor conferences in March. Details for each is as follows: Cowen 43rd Annual Health Care ConferenceDate: Wednesday, March 8, 2023Time: 10:30 am ETLocation: Boston Marriott Copley Place, Boston, MALink: Click HER
- Simply Wall St.
Institutions own 29% of MediWound Ltd. (NASDAQ:MDWD) shares but individual investors control 43% of the company
If you want to know who really controls MediWound Ltd. ( NASDAQ:MDWD ), then you'll have to look at the makeup of its...
- GlobeNewswire
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
YAVNE, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously announced registered direct offering. The gross proceeds to the Company from the offering were $27.5 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net procee
- GlobeNewswire
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
YAVNE, Israel, Feb. 03, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities purchase agreement for the sale and purchase of1,964,286 shares of the Company’s ordinary shares, par value NIS 0.07, at a purchase price of $14 per share, in a registered direct offering. The Company expec
- Simply Wall St.
MediWound (NASDAQ:MDWD) investors are sitting on a loss of 61% if they invested five years ago
This month, we saw the MediWound Ltd. ( NASDAQ:MDWD ) up an impressive 39%. But that is little comfort to those holding...
- GlobeNewswire
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the U.S. in the second quarter of 2023 YAVNE, Israel, Dec. 29, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue rep
- GlobeNewswire
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
Japan is the first country in the world to approve NexoBrid for people of all ages; pediatric and adult populations Exclusive marketing and distribution agreement with Kaken Pharmaceutical Co., Ltd. YAVNE, Israel, Dec. 23, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that its partner, Kaken Pharmaceutical Co., Ltd. has gained marketing ap
- GlobeNewswire
MediWound Strengthens European Presence of NexoBrid®
NexoBrid gained marketing approval in Switzerland; launch expected first quarter 2023 Launch in France expected in third quarter 2023 YAVNE, Israel, Dec. 20, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the marketing approval of NexoBrid® in Switzerland. MediWound has signed an agreement with Triskel Integrated Services to market and dist
- GlobeNewswire
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MW005 shown to be safe and well-tolerated Data provides clinical efficacy proof-of-concept based on complete clearance of target lesions YAVNE, Israel, Dec. 19, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company, focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Bas
- GlobeNewswire
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical companyYAVNE, Israel, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced it has gained marketing approval of NexoBrid® in India. MediWound has signed an agreement granting Bharat Serums and Vaccines Limited (B
